Back to Authors

Yurtsever, Nalan

Mayo Clinic

Yale University

Citations 2

A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever, Nalan, Jacobs, Jeremy W. , Park, Yara A. , Lauro, Deisen, Torres, Sarina, Ward, Dawn C. , Stephens, Laura D. , Adkins, Brian D. , Yurtsever, Nalan , Stephens, Laura , Tormey, Christopher A , Adkins, Brian David , Jacobs, Jeremy W , Yurtsever, Nalan , Booth, Garrett S. , Schwartz, Joseph E. , Woo, Jennifer S. , Allen, Elizabeth S. , Tormey, Christopher A.

Journal of Clinical Apheresis | July 9, 2024 | Volume: 39 | Issue: 4 | Pages: No page available

10.1002/jca.22138 Get It

AbstractIntroductionApheresis practices in the United States (US) have not been comprehensively characterized to date. This study aimed to address this gap by evaluating apheresis therapy through a national survey.MethodsA multi‐institutional survey was conducted between April and July 2023. The survey, comprising 54 questions, focused on institutional demographics, procedures, equipment, staffing, training, and impacts of the Coronavirus Disease 2019 (COVID‐19) pandemic. Responses from 22 institutions, primarily academic medical centers, were analyzed.ResultsTherapeutic plasma exchange (TPE) was the most common procedure, followed by hematopoietic progenitor cell collection (HPC‐A) and red blood cell exchange (RCE). CAR‐T cell collections were widespread, with some institutions supporting over 30 protocols concurrently. Most sites used the Spectra Optia Apheresis System, were managed by a transfusion medicine service, and employed internal apheresis providers. Insufficient staffing levels, exacerbated by the COVID‐19 pandemic, were common and most often addressed using overtime.DiscussionThe survey highlighted the ubiquity of TPE, expanding cellular collections and staffing challenges. The role of apheresis in supporting cellular therapy, particularly in newly developing cell and gene therapies and clinical trials, was evident. Staffing issues during the pandemic emphasized the need for innovative recruitment strategies.ConclusionThis nationwide survey provides the most comprehensive analysis to date of apheresis practices in large US academic centers.
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke, Olivia , Jacobs, Jeremy W. , Rinder, Henry M. , Villalba, Cristina A. Figueroa , Lee, Edward S. , Campos, Juan J Silva, Abels, Elizabeth , Yurtsever, Nalan, Yurtsever, Nalan , Lee, Edward S , Jacobs, Jeremy W , Yurtsever, Nalan , Burke, Olivia, Tormey, Christopher A.

Laboratory Medicine | December 24, 2023 | Volume: 55 | Issue: 4 | Pages: 520-523

10.1093/labmed/lmad107 Get It

Abstract The Heidenhain variant of Creutzfeld-Jakob disease (CJD) is a rare form that initially presents with visual disturbances. In early stages, the presentation can mimic neuromyelitis optica spectrum disorders (NMOSD) and lead to unnecessary treatment modalities. Herein, we describe a case of a 66-year-old man who presented with bilateral vision loss and retro-orbital discomfort. In addition to immunosuppressive therapy, he received 4 rounds of therapeutic plasma exchange after his preliminary diagnosis of NMOSD. We were surprised to note that his condition did not show improvement but deteriorated, with severe neurocognitive symptoms. Eventually, CJD was suspected, and real-time quaking-induced conversion (RT-QuIC) was performed. By the time the diagnosis of Heidenhain variant of CJD was confirmed, the patient was discharged to hospice care and died shortly after.